Opioid Addiction

Featured Article

Leveraging the Placebo Effect to Reduce Opioid Requirements

Leveraging the Placebo Effect to Reduce Opioid Requirements

Emerging evidence indicates that the placebo effect can in some instances reduce patients' pain. The current debate is whether clinicians need to disclose to patients that they are using placebos instead of active ingredients.

Latest

Opioid Use Stable in Past Decade Among Commercially Insured, Medicare Beneficiaries

Opioid Use Stable in Past Decade Among Commercially Insured, Medicare Beneficiaries

Despite increased attention to opioid abuse in the past few years, opioid use and average daily dose in individuals who are commercially insured and those receiving Medicare have remained relatively unchanged.

Cassipa Approved as Maintenance Treatment for Opioid Dependence

Cassipa Approved as Maintenance Treatment for Opioid Dependence

Cassipa combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist.

FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis

FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis

The new plan will break out the current guidance into 4 separate guidances.

Drug Dependence, Obesity Prevalence Inversely Related

Drug Dependence, Obesity Prevalence Inversely Related

The prevalence of obesity may be lower among drug-dependent individuals, particularly in those dependent on opioids, compared with the general population.

Nalbuphine Can Relieve Opioid-Induced Urine Retention

Nalbuphine Can Relieve Opioid-Induced Urine Retention

Nalbuphine can relieve opioid-induced urine retention.

Opioid Dependence More Common Before Spine Surgery

Opioid Dependence More Common Before Spine Surgery

Opioid dependence is more likely to occur in patients with degenerative spondylolisthesis (DS) before surgery than afterward.

Examining the Effect of Chronic Opioid Use on 2016 Presidential Voting Patterns

Examining the Effect of Chronic Opioid Use on 2016 Presidential Voting Patterns

Chronic use of prescription opioids was correlated with support for the Republican candidate in the 2016 presidential election.

Researchers Question DEA Hydrocodone Schedule Change in Light of Postoperative Prescribing Practice Data

Researchers Question DEA Hydrocodone Schedule Change in Light of Postoperative Prescribing Practice Data

The US Drug Enforcement Administration rescheduled hydrocodone-containing analgesics from schedule III to schedule II in October 2014.

Medicaid Expansion Under the ACA Increased Access to Opioid Use Disorder Treatments

Medicaid Expansion Under the ACA Increased Access to Opioid Use Disorder Treatments

Expansion of Medicaid eligibility under the Affordable Care Act was found to have resulted in increased access to opioid use disorder treatments for individuals with opioid medications covered by Medicaid.

DEA Proposal Will Significantly Cut Opioid Manufacturing in 2019

DEA Proposal Will Significantly Cut Opioid Manufacturing in 2019

Last year, the DEA proposed a 20% reduction in the manufacturing of controlled substances for 2018 compared to 2017.

Concomitant Use of Pregabalin and Opioids May Increase Risk for Opioid-Related Death

Concomitant Use of Pregabalin and Opioids May Increase Risk for Opioid-Related Death

Patients who are prescribed pregabalin concomitantly with opioids may be at increased risk for opioid-related death.

Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults

Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults

Personality traits such as anxiety sensitivity, hopelessness, sensation seeking, and impulsivity may be predictors of use and misuse of prescription drugs in young adults.

The Opioid Crisis: District by District

The Opioid Crisis: District by District

Southern states have the 10 highest opioid prescribing rates in the country, while California, New York, and Virginia are among the bottom 10.

Opioid Administration, Prescribing in the ED on the Decline in Recent Years

Opioid Administration, Prescribing in the ED on the Decline in Recent Years

After a rise in the frequency of opioids prescribed in emergency departments from 2005 to 2011, a decline was observed from 2012 to 2015, particularly in the 18- to 64-year age group.

Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers

Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers

Lowering the default number of opioid pills prescribed in an electronic medical record system can significantly decrease the amount of opioid medication prescribed after procedures.

Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC

Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC

The prevalence of opioid use disorder rose in women delivering at hospitals across 28 US states and the District of Columbia between 1999 and 2014, with quadrupling at the national level during this period.

Notifications by PDMPs May Not Effectively Reduce Opioid Misuse

Notifications by PDMPs May Not Effectively Reduce Opioid Misuse

Unsolicited notices to prescribers as part of prescription drug monitoring programs may not effectively reduce opioid use, as patients may seek other prescribers.

Integrating Treatments for Opioid Use Disorder and Infectious Diseases

Integrating Treatments for Opioid Use Disorder and Infectious Diseases

All healthcare providers have a role in combating the opioid use disorder epidemic and its infectious disease consequences.

Which Opioids Are More Likely to Induce QT Interval Prolongation?

Which Opioids Are More Likely to Induce QT Interval Prolongation?

Studies comparing MMT to buprenorphine maintenance treatment (BMT) over 5-years found buprenorphine to be a safer drug for opioid maintenance treatment as it had no significant effect on QT prolongation.

Assessing Medication-Assisted Treatments: FDA Guidance for Drug Developers

Assessing Medication-Assisted Treatments: FDA Guidance for Drug Developers

In a communiqué issued on August 6, 2018, the US Food and Drug Administration announced the release of a draft guidance titled, "Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Medication-Assisted Treatment - Guidance for Industry."